AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04158908 — intervention group
Intervention type: BEHAVIORAL
Intervention: Oncolo-GIST
Description: Oncolo-GIST is a brief, manualized communication intervention that guides oncologists in gist communication by itemizing 4 key steps in the process of imparting prognostic information.~Topic covered include:~1. Principles of introducing prognosis in the setting of worsened scan results~2. Coupling communicating realistic prognoses with psychological support (e.g., saying average life-expectancy is months... with emphasizing that the oncology team will always provide care for you)~3. Addressing informational needs and psychological reactions~4. Applying proven techniques for supporting patients who are reluctant to discuss prognosis.~The 4-step guide will include brief video-clips of demonstrating each talking point with a standardized patient, including ideal scenarios, common pitfalls to avoid, and how to respond to patient reactions that are particularly challenging, such as responding to optimism, death anxiety, and reliance on faith.
Study NCT03577093 — intervention group
Intervention type: OTHER
Intervention: There is no intervention at all.
Description: There is no intervention at all.
Study NCT03469154 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dyad training method
Description: The training model for paediatric basic life support for laypersons involves a course based on pairs training together guided by instructional videos and with hands-on practice on resuscitation manikins.
Study NCT03469154 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Instructor led training method
Description: The training model for paediatric basic life support for laypersons involves a course led by an instructor including hands-on practice on resuscitation manikins.
Study NCT02488252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semi-individualised Chinese Medicine treatment
Description: A: Panax ginseng, Atractylodes macrocephala, Pinellia ternate, Pericarpium citri reticulatae, Herba Pogostemonis, Glycyrrhiza uralensis, Rehmannia-6 decoction~B: Cortex magnoliae officinalis, Atractylodes macrocephala, Common Floweringquince Fruit, Common Vladimiria Root, Tsaoko Amomum Fruit, Palmae Fruit, Radixaconiti laterlis perparata, Zingiber officinale Rosc., Glycyrrhiza uralensis, Rehmannia-8 decoction~C: Root of Pilose Asiabell, Astragalus membranaceus, Rehmannia glutinosa, Common Macrocarpium Fruit, Dioscorea opposita , Barbary Wolfberry Fruit, Cortex eucommiae, Chinese Angelica, Glycyrrhiza uralensis~D: Rehmannia-6 decoction, Fructus Ligustri Lucidi, Yerbadetajo Herb~E: Rehmannia-8 decoction, Fructus Ligustri Lucidi, Yerbadetajo Herb
Study NCT02488252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Routine medical care (active comparator)
Description: Angiotensin converting enzyme inhibitor or angiotensin receptor blocker at stable dose
Study NCT02087917 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Assigned study drug (HS-25 or placebo) is to be administered orally once daily in the morning with or without food. Treatment duration 4 weeks.
Study NCT01456429 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thoracic endosonography
Description: Endobronchial-ultrasound controlled transbronchial needle aspiration (EBUS-TBNA) in combination with a transoesophageal-ultrasound controlled needle aspiration of mediastinal lymph nodes
Study NCT02012452 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tobacco treatment
Description: participants will be provided contingency management and cognitive behavioral therapy to help them quit tobacco prior to PTSD treatment
Study NCT02012452 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Health Education
Description: Participants will be provided education on a variety of health topics and will set health goals around each topic
Study NCT04104789 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Articaine Injection
Description: Local anesthetic
Study NCT04482127 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SubEpithelial connective graft
Description: Connective tissue graft harvested from hard palate, to be placed buccal to extraction sockets in the intervention group
Study NCT00867035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorine dioxide and scraper
Description: 20ml of mouthwash used for 30sec as adjunct to tongue scraper twice a day
Study NCT00867035 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine gluconate and scraper
Description: The intervention was accomplished by subject after instructions by investigator: twice a day the scraper was used for 4 strokes then 20ml 0.12% chlorhexidine gluconate rinse for 30sec, for one week.
Study NCT03391882 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APL-130277
Description: APL-130277: Part A- determine the dose; Part B- 28-day repeat dosing at the dose determined in Part A
Study NCT03391882 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: subcutaneous apomorphine
Description: subcutaneous apomorphine Part A- determine the dose; Part B- 28-day repeat dosing at the dose determined in Part A
Study NCT02464748 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TiM telehealth arm
Study NCT02488252 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Routine medical care (active comparator)
Description: Angiotensin converting enzyme inhibitor or angiotensin receptor blocker at stable dose
Study NCT06544382 — intervention group
Intervention type: OTHER
Intervention: The Long COVID Rehabilitation Intervention
Description: The intervention is a structured rehabilitation intervention with a duration of minimum 3 months comprising 4-12 individual sessions and 1-4 group-based courses delivered by physiotherapists and occupational therapists.
Study NCT03263078 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: For the maintenance of anesthesia, we used 2% propofol (Fresofol®, Fresenius Kabi, Germany) administered by the target controlled infusion (TCI) system (Orchestra® Base Primea; Fresenius Kabi, Germany) in Schnider mode with an effect concentration (Ce) of 2.5-3.5 µg ml-1
Study NCT03263078 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: Anesthesia was maintained using 1-3% sevoflurane (ULTANE®, AbbVie Inc., USA) in the Sevoflurane group.
Study NCT01828645 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Carbohydrate plus whey protein enriched drink
Description: The patients will drink 200 mL of the nutritional supplement (Jucy, Fresenius Kabi, Brazil) 2h before upper digestive endoscopy under sedation with propofol.
Study NCT00814606 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluvastatin
Description: Week 1: Fluvastatin 20mg daily Week 3: Fluvastatin 40mg daily Week 5: Fluvastatin 60mg daily Week 7: Fluvastatin 80 mg daily
Study NCT00814606 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa2a
Description: 180 mcg/ml SQ injection once a week for 48 weeks (starting at week 9)
Study NCT00814606 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin
Description: 1000-1200 mg daily orally in two divided doses for 48 weeks (starting at week 9)
Study NCT01619579 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AVACEN Thermal Exchange System
Description: Non-invasive device forms vacuum around subject's hand, enabling efficient core body temperature adjustment using heating element inside device.
Study NCT02170831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBR 1048 MS low
Study NCT02170831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBR 1048 MS medium 1
Study NCT02170831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBR 1048 MS medium 2
Study NCT02170831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBR 1048 MS high
Study NCT02170831 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BIBR 1048 MS placebo
Study NCT03710902 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ECG monitoring for 3 weeks
Description: A 3-week continuous ECG monitoring to detect occult AF.
Study NCT03710902 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-monitoring of BP and self-titration of antihypertensive medication
Description: One-week monthly self-monitoring of BP and self-titration of antihypertensive medication according to a pre-specified protocol, assisted with a mobile device application.
Study NCT01790230 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LifeSeal™ Kit
Description: Application of LifeSeal™ Kit for staple line reinforcement during open GI surgeries in Low Anterior Resection
Study NCT02896543 — intervention group
Intervention type: OTHER
Intervention: measurement
Description: Blood is obtained into ethylene diamine tetraacetic acid（EDTA） tubes from all subjects via antecubital vein puncture to measure the number of dendritic cells(DCs) and the concentration of sP-selectin. The number of dendritic cells(DCs) and the concentration of sP-selectin are measured in all patients with STEMI at 0 and 5-7 days after admission. The number of dendritic cells(DCs) and the only once in control group after admission.
Study NCT01723150 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Study NCT01723150 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ceftriaxone
Study NCT01723150 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trimethoprim/sulfamethoxazole
Study NCT01723150 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ertapenem
Study NCT03988101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 20mg
Description: Patients who are eligible for all of the criteria and who do not qualify as exclusion criteria should be enrolled in the study and randomly enrolled in a 1: 1 dose of rosuvastatin 20 mg once daily or equivalent.
Study NCT03988101 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Patients who are eligible for all of the criteria and who do not qualify as exclusion criteria should be enrolled in the study and randomly enrolled in a 1: 1 dose of rosuvastatin 20 mg once daily or equivalent.
Study NCT06544382 — intervention group
Intervention type: OTHER
Intervention: Usual care
Description: A less structured rehabilitation programme comprising individual session with a few group options with patients with long COVID or mixed diagnoses.
Study NCT00803933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DB289
Description: Pafuramidine maleate (DB289), 100 mg BID orally
Study NCT00803933 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pentamidine
Description: Pentamidine isethionate (Aventis) for injection (200 mg/vial), 4 mg/kg QD IM
Study NCT04361253 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High-Titer COVID-19 Convalescent Plasma (HT-CCP)
Description: 250mL HT-CCP x2 doses given sequentially.
Study NCT04361253 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Standard Plasma (FFP)
Description: 250mL FFP or FP24 x2 doses given sequentially.
Study NCT01235949 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: GSK1024850A (SynflorixTM)
Description: Intramuscular injection, 4 doses
Study NCT01235949 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK1024850A (SynflorixTM)
Description: Intramuscular injection, 4 doses
Study NCT00931463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: raltegravir
Description: 400 mg raltegravir tablet taken every 12 hours
Study NCT00931463 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2N(t)RTI
Description: 2N(t)RTIs as prescribed
Study NCT00931463 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ritonavir-boosted lopinavir
Description: 2 heat-stable tablets of ritonavir-boosted lopinavir taken every 12 hours
Study NCT00931463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir-boosted lopinavir
Description: 2 heat-stable tablets of ritonavir-boosted lopinavir taken every 12 hours
Study NCT02326363 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Relapse Prevention (MBRP)
Description: Each session has a central theme/topic and consists of in-session experiential practice, discussions and homework assignments. Sessions begin with a check-in followed by a 20-30 minute meditation (i.e. body scan). The therapist reviews homework assignments, discusses challenges and participants are taught a variety of MM practices such as breath meditation, urge surfing, walking or movement meditation.
Study NCT02326363 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Twelve-Step Facilitation Intervention (TSF)
Description: The primary goal is to promote abstinence by facilitating the patient's acceptance and surrender of addiction. Sessions begin with a check-in during which participants introduce themselves, report on meeting attendance and participation in related activities, any alcohol/drug use or craving to use. The remainder of the session focuses on discussion of the topic content followed by a take home summary and homework assignment.
Study NCT01529476 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levofloxacin
Description: levofloxacin 500 mg,QD,7\~10 days
Study NCT01529476 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nemonoxacin
Description: Nemonoxacin 500mg,QD,7\~10 days
Study NCT03859986 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ALX-101 Gel Vehicle
Description: ALX-101 Gel Vehicle
Study NCT03859986 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALX-101 Gel 5%
Description: ALX-101 Gel 5%
Study NCT02460926 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Scaling & Root Planing
Description: It consists in the non-surgical debridement of the sub gingival area affected by periodontal disease
Study NCT04429919 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AP-325
Description: During the 10-day double-blind treatment period (Days 1 to 10), subjects will take 4 capsules of the IMP orally once daily in the morning before breakfast.
Study NCT04429919 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: During the 10-day double-blind treatment period (Days 1 to 10), subjects will take 4 capsules of the IMP orally once daily in the morning before breakfast.
Study NCT03403686 — intervention group
Intervention type: BIOLOGICAL
Intervention: blood draw
Description: Blood sample will be obtained and CD34+ cells will be isolated for functional testing.
Study NCT02629588 — intervention group
Intervention type: BEHAVIORAL
Intervention: Multimodal or Unimodal Sensory stimulation
Description: multimodal sensory stimulation, unimodal sensory stimulation, auditory stimulation, complex stimulation, median nerve stimulation.
Study NCT04830917 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Immobilization type for mallet injury
Description: Method to hold the DIP joint in full extension to allow healing of terminal tendon injury/mallet injury
Study NCT03874559 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood Draw
Description: Serum samples will be obtained from each patient enrolled
Study NCT05478876 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: carbon ion radiation therapy CIRT
Description: CIRT: The low-dose CTV (clinical target volume) will receive a total dose of 43 GyRBE in 10 fractions, 4 fractions per week. The high-dose CTV will receive a total dose of 68.8 GyRBE in 16 fractions, 4 fractions per week.~The expected duration of treatment is 4 weeks, 4 fractions per week. Treatments lasting longer than 6 weeks, or with less than 6 fractions administered on 14 consecutive days, will not be considered acceptable.~Immunotherapy: Patients will undergo immunotherapy after carbon ion radiation therapy (CIRT) up to maximum response and/or up to tolerance. The concomitant association of immunotherapy is not envisaged in this protocol.
Study NCT02473445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cysteamine Bitartrate
Description: Cysteamine Bitartrate Delayed-release capsules
Study NCT02558868 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Study NCT02558868 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Study NCT02558868 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Study NCT02657538 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non invasive caries treatment
Description: If the active comparator does not detect cavitation, fluoride varnish is applied on the test surface.
Study NCT01856595 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06291874
Description: The dosing schedule is 5, 15, 50, 100 and 150 mg QD for 14 days for the first 5 cohorts in Part A. The dosing schedule for the first cohort in Part B is 15 mg QD for 14 days and 30 mg QD for 28 days
Study NCT02657538 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Invasive caries treatment
Description: If the active comparator does detect cavitation, a composite restauration is placed
Study NCT02657538 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Near-infrared light transillumination device (DIAGNOcam, KaVo, Biberach, Germany)
Study NCT02657538 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Visual examination and bitewing (BW) radiography
Description: established diagnostic methods
Study NCT01856595 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets will be administered QD in each of the cohorts for 14 days (Part A cohorts 1- 5 and Part B cohort 1) or 28 days (Part B cohort 2).
Study NCT01081873 — intervention group
Intervention type: DRUG
Intervention: leuprolide (Lucrin/Lucrin-Tri-depot)
Description: Subcutaneous or intramuscular administration for all participants
Study NCT00697047 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Automated Mailing
Description: Usual Care plus Automated mailing
Study NCT00697047 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Automated Mailing Plus Assisted
Description: If not screened after automated mailing, MA assists with screening.
Study NCT00697047 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Auto Plus Assisted Plus Navigation
Description: If not screened after automated mailing and assistance by MA, RN begins navigation.
Study NCT03992768 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hamamatsu NanoZoomer S360MD Digital Slide Scanner System
Description: Detection of pathology features using whole slide imaging
Study NCT03825276 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mango consumption
Description: Daily consumption of 280 g of frozen mangos during 8 weeks. The daily dose in equivalent to a 2-cups serving.
Study NCT00187837 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SW
Description: Stepwise removal of carious tissue in 2 stages
Study NCT00187837 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: DCE
Description: one complete excavation
Study NCT01030536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAT-8015 20 mcg/kg
Description: Participants will receive 20 mcg/kg Moxetumomab pasudotox (CAT-8015) as an intravenous (IV) infusion over 30 minutes on Days 1, 3, and 5 of every 28-day cycle.
Study NCT01483014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imatinib mesylate
Study NCT04604431 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: iREACH CDS Tool
Description: Pediatric clinicians in the intervention arm will 1) receive the iREACH education module, 2) have the iREACH CDS tool integrated into the EHR templates for use at the 4-, 6-, 9-, 12-month WCC, and 3) will be reminded by EHR-embedded prompts at the 9-month WCC to ask caregivers whether peanuts were introduced and tolerated.
Study NCT00552136 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ankle Arthroplasty
Study NCT00552136 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ankle Arthrodesis
Description: Ankle fusion surgery
Study NCT06126159 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: multiparametric and fat-detection magnetic resonance imaging (MRI)
Description: Differentiating of renal AMLs with minimal fat and RCCs
Study NCT03940248 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton Accelerated Partial Breast Irradiation
Description: 38.5 Cobalt Gray Equivalent (CGE) given over 10 fractions
Study NCT02494414 — intervention group
Intervention type: OTHER
Intervention: Long-term follow-up
Description: Vital and neurological follow-up
Study NCT03923335 — intervention group
Intervention type: OTHER
Intervention: DNA methylation detection
Description: detecting the methylation status of colorectal cancer specimen
Study NCT02149966 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG-348
Description: A range of doses of AG-348 will be tested based on the assessment of safety and tolerability. AG-348 will be administered by mouth (orally) each day for a period of 14 days.
Study NCT02149966 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered by mouth (orally) each day for a period of 14 days.
Study NCT01542788 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF
Description: Sofosbuvir (SOF) 400 mg tablet administered orally once daily
Study NCT01542788 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV
Description: Ribavirin (RBV) was administered as a tablet orally according to package insert weight-based dosing recommendations (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg).